Marie Courbebaisse

Affiliations: - Physiology Department, Renal Explorations Unit, headed by Pr. Houillier, Hôpital Européen GeorgesPompidou 20, rue Leblanc, 75908 Paris cedex 15, France - INSERM U1151-CNRS UMR8253, INEM. Team 12, Fabiola Terzi, «Mechanisms and therapeutic strategies of chronic kidney disease», Paris, France - University of Paris Cité (Université de Paris Cité), Paris, France University course: -2002: Master degree in Biological and Medical Sciences, Clermont-Ferrand I University, France -2003: Postgraduate degree in Epithelium Biology and Pathology, Paris VII University 2004 Dissertation for the requirement of MD degree, Clermont-Ferrand I University, France -2004: Medical specialty certification (Nephrology), Clermont-Ferrand I University 2007, University degree « Nephrolithiasis », Paris XI University, France -2009: PhD degree in Physiology and Physiopathology, ‘Characterization of the functional consequences of a new human NHERF1 mutation located in the PDZ1 domain and clinical studies about mineral metabolism after renal transplantation’, Paris VI University, France -2015: University degree «Training to animal experimentation, level: Project designer », Paris V University, France -From June 2016 to September 2017: Mobility and post-doc carried out in the laboratory of Pr. Lanske, Division of Bone and Mineral Research, Harvard School of Dental Medicine, Harvard University, Boston, USA - 2018: Authorization to supervise Research, Paris V University, France - 2019: University degree «Medical Pedagogy», Paris V, VI, XI and XII Universities Clinical course: -1999-2004 : Senior resident (Interne des Hôpitaux de Clermont-Ferrand) -2004-2005: Hospital Practitioner in Dialysis and Nephrology Unit, Tenon Hospital, Paris, France -2005-2008: Assistant Professor-Chief resident in Renal Physiology, Necker Hospital, Paris V University, Paris, France -2008-2012: Hospital Practitioner in Dialysis and Nephrology Unit, Tenon Hospital, Paris, France -2013-2020 Associate Professor-Hospital Practitioner, Physiology Department, Georges Pompidou European Hospital, Paris, France and University of Paris, Paris, France -2020-now: Full Professor-Hospital Practitioner, Physiology Department, Georges Pompidou European Hospital, Paris, France and University of Paris, Paris, France Major Funded Clinical Trials: - 2021-now. PI of the European registry of patients with cystinuria EUROCYS under the aegis of ERKNET (European rare kidney disease reference network). Financial support from Advicenne Laboratory. - 2020: PI of the the “COVID-HOP study :Identification of markers associated with the risk of infection by SARS -CoV2 and those associated with the asymptomatic COVID + status versus symptomatic COVID + thanks to the constitution of a biological collection during the SARSCoV-2 serological screening in hospitalprofessionals” Funding of 680 000 Euros (AXA research fund, University of Paris, Paris and French Hospitals fundation). NCT: 04418375. - 2020: PI for “EFIC-RES Exploration of the role of FGF23 and its C-terminal fragment in the insufficiency chronic respiratory system ” Funding of 24,000 Euros from the Research Fund of the University of Paris. NCT05258370 - 2016: PI for the study \"EUGENIA: Vascular Remodeling After Linving Kidney Donation Study \" Funding of 20,000 Euros obtained from the French Biomedicine Agency. NCT05073913 - 2014-now: PI for the Study “Effect of Urine Alkalinazation on Urinary Inflammatory Markers in Patients With Cystinuria ». Supported by INSERM and the industry (Biohealth, Italia: 16,000 Euros). NCT03836144 - 2013-now: PI of the multiGFR study (Validation of New Markers of Glomerular Filtration Rate: DotaGadolinium and Calcium-EDTA); French National Funding: 400,000 Euros, Co-funded by the industry (Biopal-USA): $47,000. NCT02286258 - 2010-now: Scientific leader of the VITALE study (VITamin D Supplementation in RenAL Transplant Recipients); French national funding: 432,000 (2010) Euros+ 39,000 (2015) Euros, Co-funded by the industry (Crinex-France): 200,000 Euros. NCT01431430 - 2010: Co-investigator and member of the scientific committee of the FEPED study (Vitamin D and pre-eclampsia); French National Funding: 530,000 Euros. NCT01648842 Areas of expertise: nephrolithiasis, cystinuria, mineral metabolism, FGF23, vitamin D, phosphate, glomerular filtration rate, living kidney donors Reviewing activities for: Kidney International, Journal of the American Society of Nephrology, American journal of Transplantation, Clinical Journal of the American Society of Nephrology, BMC Nephrology, Nutrients Ten most relevant original scientific publications (among 106 publications on Pubmed): 1. Effect of Urine Alkalization on Urinary Inflammatory Markers in Cystinuric Patients. Caroline ProtBertoye, MD, PhD1,2,3,4,5,6*, Vincent Jung, PhD7*, Isabelle Tostivint, MD6,8,9,10* , Kevin Roger,PhD7 , Jean-François Benoist, Pharm D, PhD11,12, Anne-Sophie Jannot, MD, PhD13, Alexis Van Straaten13 , Bertrand Knebelmann,MD, PhD14,15,16, Ida Chiara Guerrera, PhD7$ , Marie Courbebaisse, MD, PhD1,4,5,6,14,16$ ., Clinical Kidney Journal, 2024, under press 2. Nonskeletal and skeletal effects of high doses versus low doses of vitamin D3 in renal transplant recipients: Results of the VITALE (VITamin D supplementation in renAL transplant recipients) study, a randomized clinical trial. Courbebaisse M, Bourmaud A, Souberbielle JC, Sberro-Soussan R, Moal V, Le Meur Y, Kamar N, Albano L, Thierry A, Dantal J, Danthu C, Moreau K, Morelon E, Heng AE, Bertrand D, Arzouk N, Perrin P, Morin MP, Rieu P, Presne C, Grimbert P, Ducloux D, Büchler M, Le Quintrec M, Ouali N, Pernin V, Bouvier N, Durrbach A, Alamartine E, Randoux C, Besson V, Hazzan M, Pages J, Colas S, Piketty ML, Friedlander G, Prié D, Alberti C, Thervet E.Am J Transplant. 2023 Mar;23(3):366-376. doi: 10.1016/j.ajt.2022.12.007. PMID: 36695682 Clinical Trial. 3. Adverse events associated with currently used medical treatments for cystinuria and treatment goals: results from a series of 442 patients in France. Prot-Bertoye C, Lebbah S, Daudon M, Tostivint I, Jais JP, Lillo-Le Louët A, Pontoizeau C, Cochat P, Bataille P, Bridoux F, Brignon P, Choquenet C, Combe C, Conort P, Decramer S, Doré B, Dussol B, Essig M, Frimat M, Gaunez N, Joly D, Le Toquin-Bernard S, Méjean A, Meria P, Morin D, N'Guyen HV, Normand M, Pietak M, Ronco P, Saussine C, Tsimaratos M, Friedlander G, Traxer O, Knebelmann B, Courbebaisse M; French Cystinuria Group.BJU Int. 2019 Nov;124(5):849-861. doi: 10.1111/bju.14721. Epub 2019 Mar 25.PMID: 30801923 4. Vitamin D status during pregnancy and in cord blood in a large prospective French cohort. Courbebaisse M, Souberbielle JC, Baptiste A, Taieb J, Tsatsaris V, Guibourdenche J, Senat MV, Haidar H, Jani J, Guizani M, Jouannic JM, Haguet MC, Winer N, Masson D, Elie C, Benachi A.Clin Nutr. 2019 Oct;38(5):2136-2144. doi: 10.1016/j.clnu.2018.08.035. Epub 2018 Aug 31.PMID: 30224306 5. Parathyroid hormone controls paracellular Ca2+ transport in the thick ascending limb by regulating the tight-junction protein Claudin14. Sato T, Courbebaisse M, Ide N, Fan Y, Hanai JI, Kaludjerovic J, Densmore MJ, Yuan Q, Toka HR, Pollak MR, Hou J, Lanske B.Proc Natl Acad Sci U S A. 2017 Apr 18;114(16):E3344-E3353. doi: 10.1073/pnas.1616733114. Epub 2017 Apr 3.PMID: 28373577 6. Carboxy-terminal fragment of fibroblast growth factor 23 induces heart hypertrophy in sickle cell disease. Courbebaisse M, Mehel H, Petit-Hoang C, Ribeil JA, Sabbah L, Tuloup-Minguez V, Bergerat D, Arlet JB, Stanislas A, Souberbielle JC, Le Clésiau H, Fischmeister R, Friedlander G, Prié D.Haematologica. 2017 Feb;102(2):e33-e35. doi: 10.3324/haematol.2016.150987. Epub 2016 Oct 27.PMID: 27789679 7. Estimated or Measured GFR in Living Kidney Donors Work-up? Gaillard F, Flamant M, Lemoine S, Baron S, Timsit MO, Eladari D, Fournier C, Prot-Bertoye C, Bertocchio JP, Vidal-Petiot E, Lamhaut L, Morelon E, Péraldi MN, Vrtovsnik F, Friedlander G, Méjean A, Houillier P, Legendre C, Courbebaisse M. Am J Transplant. 2016 Oct;16(10):3024-3032. doi: 10.1111/ajt.13908. Epub 2016 Jul 15.PMID: 27273845 8. Association of mGFR of the Remaining Kidney Divided by Its Volume before Donation with Functional Gain in mGFR among Living Kidney Donors. Courbebaisse M, Gaillard F, Tissier AM, Fournier C, Le Nestour A, Corréas JM, Slimani-Thevenet H, Martinez F, Léon C, Eladari D, Timsit MO, Otal P, Hignette C, Friedlander G, Méjean A, Houillier P, Kamar N, Legendre C.Clin J Am Soc Nephrol. 2016 Aug 8;11(8):1369-76. doi: 10.2215/CJN.12731215. Epub 2016 May 17.PMID: 27189317 9. CKD and Its Risk Factors among Patients with Cystinuria. Prot-Bertoye C, Lebbah S, Daudon M, Tostivint I, Bataille P, Bridoux F, Brignon P, Choquenet C, Cochat P, Combe C, Conort P, Decramer S, Doré B, Dussol B, Essig M, Gaunez N, Joly D, Le Toquin-Bernard S, Méjean A, Meria P, Morin D, N'Guyen HV, Noël C, Normand M, Pietak M, Ronco P, Saussine C, Tsimaratos M, Friedlander G, Traxer O, Knebelmann B, Courbebaisse M; French Cystinuria Group.Clin J Am Soc Nephrol. 2015 May 7;10(5):842-51. doi: 10.2215/CJN.06680714. Epub 2015 Feb 25.PMID: 25717071 10. A new human NHERF1 mutation decreases renal phosphate transporter NPT2a expression by a PTHindependent mechanism. Courbebaisse M, Leroy C, Bakouh N, Salaün C, Beck L, Grandchamp B, Planelles G, Hall RA, Friedlander G, Prié D.PLoS One. 2012;7(4):e34764. doi: 10.1371/journal.pone.0034764. Epub 2012 Apr 10.PMID: 22506049